Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Clavis

- PMLiVE

Stem cell therapy trial shows promising results for treating progressive MS

The early-stage trial shows the potential to develop an advanced cell therapy treatment

Bayer symbol

Bayer and BlueRock announce positive results from Parkinson’s cell therapy trial

Phase 1 results suggest the stem cell-based treatment improves symptoms of the condition

- PMLiVE

ReNeuron set for recovery after Woodford stake sale

Edison analyst says sale should help shares to stabilise

How do you define a biotech company?

In the coming weeks we will be releasing a report that looks in detail at the commercial challenges and opportunities that a modern day biotech company faces. But before then,...

Blue Latitude Health

Bayer symbol

Bayer helps bankroll new stem cell company BlueRock

Start-up receives $225m to develop cardiovascular and neurodegenerative disease therapies

- PMLiVE

Stem cell therapy promising for rheumatoid arthritis

Mesoblast’s phase II trial sees "impressive efficacy" in refractory patients

- PMLiVE

ReNeuron aiming to take second stem cell therapy into clinic

Will test its human retinal progenitor cell for genetic eye disease RP

- PMLiVE

ReNeuron makes shifts and additions to senior team

Including Sharon Grimster being named as general manager for Wales

- PMLiVE

ReNeuron appoints new CEO

Olav Hellebø joins from Clavis Pharma

- PMLiVE

ReNeuron wins orphan status for stem cell therapy

ReN003 is being assessed as a treatment for rare eye disorder retinitis pigmentosa

- PMLiVE

Government funding brings ReNeuron to Wales

Stem cell specialist moves from former base in England

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links